DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20221919

A study on micronucleus frequency in cervical smear as biomarker for genetic damage in polycystic ovarian syndrome

Showri R., Rajini T.

Abstract


Background: Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder with metabolic and reproductive consequences. Genomic damage and susceptibility to cancer are noteworthy concerns in PCOS. Relationship between PCOS and endometrial and ovarian cancer has already been established. The presence of high body mass index, excess triglycerides, oxidative stress and occurrence of metabolic syndrome is a frequent occurrence in PCOS. This may succeed into genetic damage and susceptibility to cervical cancer as they are also known risk factors of the same. The aim of the study was to estimate the frequency of micronuclei in cervical smear and to determine if it can be used as a biomarker of genomic instability and susceptibility to cervical changes in the future in PCOS.

Methods: This observational case control study included 38 subjects diagnosed with PCOS by Rotterdam’s criteria and 38 controls and was conducted between September 2018 to March 2020 in VIMS and RC. Data regarding age and anthropometric details and cervical smear samples was collected from all the subjects. The frequency of micronuclei in cervical smears was expressed as mean±standard deviation (SD). Differences between the PCOS group and the control group were examined for statistical significance using two-sample independent t-test. A p value of ≤0.05 denoted statistically signifi­cant difference.

Results: The mean±SD of micronuclei frequencies in cervical smears was observed to be 1.69±0.69 and 0.33±0.18 (p value <0.0001) in the subjects with PCOS and control group, respectively.

Conclusions: Micronuclei frequency was found to be elevated in cervical smears of women with PCOS when compared to controls indicating genetic instability and probable susceptibility to cervical cancer in the future in women with PCOS.

 


Keywords


Micronucleus, PCOS, Biomarker

Full Text:

PDF

References


Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Human Reprod Sci. 2020;13(4):261.

Joo YY, Actkins KE, Pacheco JA, Basile AO, Carroll R, Crosslin DR, et al. A polygenic and phenotypic risk prediction for polycystic ovary syndrome evaluated by phenome-wide association studies. J Clin Endocrinol Metab. 2020;105(6):1918-36.

Gur EB, Karadeniz M, Turan GA. Fetal programming of polycystic ovary syndrome. World J Diabetes. 2015;6(7):936.

Barsky M, Merkison J, Hosseinzadeh P, Yang L, Bruno-Gaston J, Dunn J, Gibbons W, Blesson CS. Fetal programming of polycystic ovary syndrome: Effects of androgen exposure on prenatal ovarian development. J Steroid Biochem Mol Biol. 2021;207:105830.

Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol. 2002;147(6):717-26.

Nersesyan A, Martirosyan A, Parsadanyan G, Zalinyan G. Chromosomal aberrations level in peripheral blood lymphocytes of women with polycystic ovary syndrome. Journal-Balkan Union Oncol. 2006;11(4):477.

Zuo T, Zhu M, Xu W. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. Oxid Med Cell Longev. 2016;8589318.

Luzhna L, Kathiria P, Kovalchuk O. Micronuclei in genotoxicity assessment: from genetics to epigenetics and beyond. Front Genet. 2013;4:131.

Gandhi G, Kaur B, Elevated frequency of Micronuclei in uterine smears of cervix cancer patients. Caryologia. 2003;56:2:217-22.

Bonassi S, El-Zein R, Bolognesi C, Fenech M. Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies. Mutagenesis. 2011;26(1):93-100.

Hamurcu Z, Bayram F, Kahrıman G, Dönmez-Altuntas H, Baskol G. Micronucleus frequency in lymphocytes and 8-hydroxydeoxyguanosine level in plasma of women with polycystic ovary syndrome. Gynecol Endocrinol. 2010;26(8):590-5.

Moran LJ, Noakes M, Clifton PM, Norman RJ, Fenech MF. Genome instability is increased in lymphocytes of women with polycystic ovary syndrome and is correlated with insulin resistance. Mutation Res/Fundament Mol Mechanisms Mutagenesis. 2008;639(1-2):55-63.

Yesilada E, Sahin I, Ozcan H, Yildirim IH, Yologlu S, Taskapan C. Increased micronucleus frequencies in peripheral blood lymphocytes in women with polycystic ovary syndrome. Eur J Endocrinol. 2006;154(4):563-8.

Karataylı R, Zamani AG, Gezginç K, Tuncez E, Soysal S, Karanfil F, Acar A, Yıldırım MS. Micronuclei frequencies in lymphocytes and cervical cells of women with polycystic ovarian syndrome. Turkish J Obstet Gynecol. 2017;14(3):151.

Balen A. Polycystic ovary syndrome and cancer. Human reproduction update. 2001;7(6):522-5.

Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78(8):782-5.

Chittenden B, Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Bio Med Online. 2009;19(3):398-405.

Ulmer H, Bjorge T, Concin H, Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me–Can). Gynecol Oncol. 2012;125(2):330-5.

Rotterdam ES. ASRM SPONSORED PCOS CONCENSUS WORKSHOP GROUP. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004;81(1):19-25.

Zehra SA. Micronucleus scoring: an available approach in the evaluation of genomic damage in exfoliative cervicovaginal cells. Ann Cytol Pathol. 2022;5(1):64-7.

Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84(6):1897-9.

Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): current perspectives. Application Clin Genetics. 2019;12:249.

Jahanfar S, Eden JA, Warren P, Seppala M, Nguyen TV. A twin study of polycystic ovary syndrome. Fertil Steril. 1995;63:478-86.

Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100-4..

Pansarasa O, D'antona G, Gualea M, Marzani B, Pellegrino M, Marzatico F. " Oxidative stress": effects of mild endurance training and testosterone treatment on rat gastrocnemius muscle. Eur J Appl Physiol. 2002;87(6):550-5.

Jelic MD, Mandic AD, Maricic SM, Srdjenovic BU. Oxidative stress and its role in cancer. J Cancer Res Therap. 2021;17(1):22.

Schildkraut JM, Schwingl PJ, Bastos E. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynaecol. 1996;88:554-9.

Shah D, Patil M, National PCOS Working Group. Consensus statement on the use of oral contraceptive pills in polycystic ovarian syndrome women in India. J Human Reprod Sci. 2018;11(2):96.

Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. The Lancet. 2007;370(9599):1609-21.

Yadav AS, Jaggi S, Buccal Micronucleus Cytome Assay- A Biomarker of Genotoxicity. J Mol Biomark Diagn. 2015;6:236.

Bhat A, Vijaya C, Padmasri R. Apoptosis and micronucleus in cervical pap smears: promising assays to increase the diagnostic value of the test. Ann Pathol Lab Med. 2016;3(4):320-8.

Bueno CT, Silva CM, Barcellos RB, Silva JD, Santos CR, Menezes JE, Menezes HS, Rossetti ML. Association between cervical lesion grade and micronucleus frequency in the Papanicolaou test. Genet Mol Biol. 2014;37:496-9.

Clarke MA, Fetterman B, Cheung LC, Wentzensen N, Gage JC, Katki HA, Befano B, Demarco M, Schussler J, Kinney WK, Raine-Bennett TR. Epidemiologic evidence that excess body weight increases risk of cervical cancer by decreased detection of precancer. J Clin Oncol. 2018;36(12):1184.

Lacey Jr JV, Swanson CA, Brinton LA, Altekruse SF, Barnes WA, Gravitt PE, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003;98(4):814-21.

Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8(1):1-10.

Kumbak B, Oral E, Bukulmez O. Female obesity and assisted reproductive technologies. Semin Reprod Med. 2012;30(6):507-16.

Wang JX, Davies MJ, Norman RJ. Obesity increases the risk of spontaneous abortion during infertility treatment. Obes Res. 2002;10(6):551-4.

Zaki M, Basha W, El-Bassyouni HT, El-Toukhy S, Hussein T. Evaluation of DNA damage profile in obese women and its association to risk of metabolic syndrome, polycystic ovary syndrome and recurrent preeclampsia. Genes Dis. 2018;5(4):367-73.

Tehrani FR, Minooee S, Azizi F. Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study. Eur J Endocrinol. 2014;171(2):199-207.

Thangavelu M, Godla UR, Godi S, Paul SF, Maddaly R. A Case-controlled Comparative Hospital-based Study on the Clinical, Biochemical, Hormonal, and Gynecological Parameters in Polycystic Ovary Syndrome. Indian J Pharm Sci. 2017;79(4):608-16.